Idiopathic nephrotic syndrome (INS) is the most glomerular disease that occurred in childhood with high rate morbidity. Glucocorticoid is drug of choice for INS and responsiveness to this drug determined prognosis. 
Idiopathic nephrotic syndrome (INS) is the most glomerular disease occurred in childhood, account for 85% from all children with nephrotic syndrome [1, 2] . Annual incidence of nephrotic syndrome in healthy children is estimated 2 to 7 cases per 100,000 children younger than 18 years of age. The peak age of onset occurs at 2 to 3 years, and approximately 50% of affected children are ages 1 to 4 years; 75% are younger than age 10 years [3] . Hospitalization rate of INS in dr Saiful Anwar Hospital, Malang, Indonesia from January 2002 until Desember 2006 was 101 cases (34% from 297 cases in nephrologic inpatient wards) [4] .
Mechanism that underlying pathogenesis of nephrotic syndrome is still unclear. Nephrotic syndrome is mediated by immunologic abnormalities.
There is an evidence that nephrotic syndrome caused by circulating factor, T-cell associated, which can cause podocyte disfunction lead to massive proteinuria [5] . Some evidence showed association between INS (primary immunologic impairment) and imbalance of Th1 and Th2 subtype as immunoregulator [1, 6, 7] . In vitro study using peripheral blood mononuclear cell (PBMC) isolated from INS patients showed increase level of various cytokines such as Interleukin (IL)-1 IL-2, IL-4 and tumor necrosis factor (TNF)-α, compared to control group or INS patients at remission state group. Other study using PBMC from patients with INS showed decrease of IL-10 serum level and increase of IL-12 and IL-18 serum level compared to control group [8] .
Glucocorticoid is drug of choice for INS and responsiveness to this drug determined prognosis [9] . Approximately 85%-90% patients with INS have a good response to glucocorticoid therapy and remit completely from proteinuria, otherwise 10%-15% have a partial or no response to glucocorticoid treatment [9, 10] . The mechanism underlying unresponsiveness to glucocorticoid treatment is complex. It based on physiologic process that involved in glucocorticoid signaling. Glucocorticoid bind to cytoplasmic glucocorticoid receptor (GR), and then translocate to nucleus and regulate transcription process of several protein include cytokines [10] [11] [12] [13] . Glucocorticoid downregulate transcription of pro-inflammatory cytokines such as IL-1, IL-2, IL-6, IL-8, IL-11, IL-12, TNF-α, Interferon gamma (IFN)-γ, granulocyte-macrophage colony stimulating factor (GM-CSF) and upregulate transcription of anti-inflammatory cytokines as IL-4 and IL-10 [14] .
Interleukin-10 is an anti-inflammatory cytokine and has multiple role in immune response include modulate Th1/Th2 response via APC (Antigen Presenting Cells) and directly inhibit proliferation and cytokine synthesis by T cells [15] [16] [17] . In steroid resistant asthmatic patient, IL-10 increase GR expression via T CD4+ cells. Ligand-induced GR downregulation can be reserved by vitamin D3. Vitamin D3 interact with glucocorticoid signaling. Administered active form of vitamin D3 increase dexamethasone-induced IL-10 expression by regulatory T cells in steroid resistant asthmatic patient. Pre-incubation T cell with IL-10 and vitamin D3 can improve impairment IL-10 release from T cell that induced by dexamethasone [18] .
Active form of vitamin D3, 1,25(OH)2-dihydroxyvitamin D3, not only has a role in calcium metabolism but also modulate immune response [19] . Terrier, et al. showed that vitamin D was safe and induced decrease of memory B cells, increase Treg and decrease Th1 and Th17 effector cells [20] . In vitro study of T CD4 
Study Design
This experimental study was conducted in pediatric nephrology policlinic and pediatric nephrology inpatient ward at dr. Saiful Anwar Hospital, Malang, Indonesia between October 2013 and April 2014. During this period 24 children in the age group 4-12 years with new onset idiopathic nephrotic syndrome (INS) were prospectively studied. Design of this study was an experimental study with randomized clinical trial, double blind, pre and post test control group. Blood samples (GR assays and IL-10 assay) obtained two times (before and after treatment). 24 patients divided into 4 groups consist of new onset INS that treated with prednisone only as a first group, new onset of INS treated with combination of prednisone and vitamin D3 as a second group, rare relaps INS treated with prednisone only as the third group, and rare relaps INS treated with combination of prednisone and vitamin D3 as the forth group. Prednisone was given orally at dose 2 mg/kg/day for 4 weeks. Vitamin D3 (D-Vit, GraciaPharmindo) also given orally at dose 2000 IU for 4 weeks. This study had been approved by Ethical Committee of dr. Saiful Anwar Hospital Malang, Indonesia.
Patients
Blood samples were obtained from 24 patients (19 males, 31 females, aged 4-12 years) with nephrotic syndrome and had received treatment both in nephrology polyclinic and inpatient ward during experimental study. Inclusion criteria include: diagnosed as idiopathic nephrotic syndrome (classified as first diagnosed and intermittent relapse), age range between 1-14 years old, approved by parents to participate in this study. Exclusion criteria for this study: secondary and congenital nephrotic syndrome, frequent relapse nephrotic syndrome, and steroid resistance nephrotic syndrome. Subjects that met the inclusion criteria randomized using randomization table.
PBMC Isolation
Blood sample transferred from collection vacuum tubes (previously mixed with anticoagulant EDTA) to a 50 mL tube. An equal volume of PBS was added and sample was mixed by repeated pipetting. The second 50 mL tube was prepared and filled with Ficoll-Hipaque (d=1.077 g/mL). This Ficoll-Hipaque solution carefully layer with the diluted blood with equal volume and then centrifuged at 1000 rpm for 30 minutes. PBMC layer was removed (second layer) using micropipette and transfered to a new 15 mL centrifuge tube. After washing two times using PBS 10 mL and centrifuge at 1200 rpm for 10 minutes, decant the supernatant and re-suspend the cell pellet in appropriate volume of PBS.
Assay for CD3 + GR Expression Phycoerythrin (PE)-labelled antihuman CD357 (GITR) (antibody cat# 311604, Biolegend, USA) and FITC-labelled anti-human CD3 (antibody cat# 344804, Biolegend, USA) were used for intracelullar staining (flowcytometry). T cell lymphocyte added with cell staining buffer (2% fetal bovine serum in PBS). Five µl pellet from PBMC isolation was taken and ready for staining using FITC-labelled anti-human CD3. 50 µl diluted antibody was taken and mixed with T cell lymphocyte and then incubated for 20 minutes (in dark room temperature). After this incubation, samples were ready for GR staining. Cell were washed with 500 µl cell staining buffer, centrifuged at 4°C, 2500 rpm for 3 minutes. After removing the supernatant, T cell lymphocyte washed with 500 µl fix buffer solution, homogenized and centrifuged at 4°C, 2500 rpm for 3 minutes. Supernatant were removed, T cell lymphocyte fixed with 500 µl fix buffer and then incubated for 20 minutes (in dark room temperature). After incubation, samples were centrifuged at 4°C 2500 rpm for 3 minutes. Supernatant were removed, and then cells washed again, re-suspend in permeabilization buffer. Suspensions were centrifuged again at 4°C, 2500 rpm for 3 minutes. After removing the supernatant, cells were ready for cell surface staining with PE-labelled anti-human CD357 (GITR) antibody (1:250). Each solution stained with 50 µl PE anti-human CD357 (GITR) diluted antibody, incubated at dark room for 20 minutes, and then washed with 500 µl permeabilization wash buffer solution. After centrifugation at 4°C, 2500 rpm for 3 minutes, supernatant were removed and added with 350 µl cell staining buffer. Cell samples were run on FACS Calibur flowcytometer and analyzed by BD Cell Quest Pro software.
Assay for CD4 + IL-10 + Expression PerCP/Cy5.5-labelled anti-human IL-10 (cat# 501418, Biolegend, USA) and FITC-labelled anti-human CD4 antibody (cat# 300506, Biolegend,USA) intracellular staining (flowcytometry). T lymphocytes CD4 + added with cell staining buffer (2% fetal bovine serum in PBS). Five µl pellet from PBMC isolation was taken and ready for staining using FITC-labelled antihuman CD4. 50 µl diluted antibody was taken and mixed with T cell lymphocyte and then incubated for 20 minutes (in dark room temperature). After this incubation, sample was ready for IL-10 intracellular staining. Cells were washed with 500 µl cell staining buffer, centrifuged at 4°C, 2500 rpm for 3 minutes. After removing the supernatant, T lymphocytes CD4 
Statistical Analysis
The normality of distribution was confirmed by the Saphiro-Wilk'sW-test (normal distribution assumed as Sig or p>0.05). The difference in IL-10 expression in particular lymphocyte subpopulations between prednisone-only and combination of prednisone and vitamin D3 treated group confirmed by one-way ANOVA (Kruskal-Wallis test as an alternative test). The diference in IL-10 expression before and after treatment confirmed by paired t-test (Wilcoxon test as an alternative). Correlation between IL-10 expression with outcome and GR expression among patients that given vitamin D3 as adjuvant (steroid sensitive or steroid resistant nephrotic syndrome) confirmed by regression test. Data were analyzed using SPSS for Windows 17.0. (confidence interval 95%).
This study involved 24 patients age ranged from 4-12 years with nephrotic syndrome (12 patient new-on-set nephrotic syndrome and 12 patients rare relaps nephrotic syndrome). Patients divided randomized into 4 treated groups. The first and second group consists of 6 patients with new onset nephrotic syndrome. First group treated with prednisone only, and second group treated with combination of prednisone and vitamin D3. The third and fourth group consists of 6 patient with rarery relapsing nephrotic syndrome. The third group treated with prednisone only, and fourth group treated with combination of prednisone and vitamin D3. Among all groups, there was no drop out. During 4 weeks treatment, patients were not showed any illness or adverse drug reactions caused by prednisone or vitamin D3. (Figure 1 ). There were also significant differences of CD4 + IL10 + expression mean (t-test, p= 0.008) between new-onset nephrotic syndrome before (3.50±3.01) and after treatment (9.53±3.89) that treated with combination prednisone and vitamin D3. This finding showed that combination prednisone and vitamin D3 administration increase IL-10 expression (Figure 2 ).
There was a significant difference of CD4 also a significant different of CD4 + IL10 + expression between first group and third group (rarely relapsing nephrotic syndrome treated with combination of prednisone and vitamin D3), and also first group and fourth group (rarely relapsing nephrotic syndrome treated with prednisone only) ( Table 2) In this study we find that there was a significant differences of IL-10 expression between new-onset nephrotic syndrome and rare relaps nephrotic syndrome after treatment with prednisone or prednisone + vitamin D3. CD4 Increase of CD4 + IL-10 + expression after glucocorticoid treatment consistent with previous study conducted by Barrat, et al. (2002) that showed glucocorticoid not only increase IL-10 production in T lymphocyte, but also decrease production of IL-4, IL-5 and IL-13 in human T CD4 + cells [22] . Other study showed that renal T CD4 + cells was the source of endogenous IL-10 [23] . Glucocorticoid treatment not only up-regulate IL-10 secretion by macrophage/ dendritic cells and Th2 cells, but also involved in Treg proliferation, major immunoregulatory T lymphocyte subtype that can produce IL-10 abundantly [23] . Glucocorticoid can also trigger IL-10 secretion by T CD4 + cells directly [24] . Other cells that can be induced to produce IL-10 is monocyte. Mozo, et al. (2004) showed that monocyte, not T or B cells, up-regulate IL-10 production (IL-10 protein and mRNA) after treatment with physiologic dose of dexamethasone (after 12 hour). This study suggest that dexamethasone treatment can induce IL-10 production at transcriptional level [25] . 1,25(OH)2D3 play an important role for T lymphocyte proliferation and differentiation. T lymphocyte treatment using calcitriol or its analogs inhibit secretion of various pro-inflammatory cytokines from Th1, Th9 and Th22 cells but induce anti-inflammatory cytokines production from Th2 cells. Calciotropic action of vitamin D was suggestion for vitamin D treatment in clinical nephrology. 1,25(OH)2D3 proven has antiproteinuria effect and inhibit renin angiotensin aldosterone system (RAAS). 1,25(OH)2D3 has a beneficial effect in preserve podocyte structural integrity and functional and also suppress renin expression directly at transcriptional level [31] .
T can also influence T cell behavior, promote tolerance through Th2 and Treg activity induction and Th1 and Th17 cell activity suppression [31] .
In this study, there was no correlation between CD4 + IL10 + expression and clinical outcome. This finding is not consistent with other study that showed short term IL-10 expression could improve glomerulonephritis and glomerulosclerosis. Potential mechanism underlying renoprotective effect of IL-10 maybe complex because IL-10 has a dual action. Major effects of IL-10 are inhibit activation and effector function of T cells, monocytes, and macrophages. IL-10 bind to its receptor (IL-10R), which this binding can activate several signaling pathway depend on cell type, include pathway that depend on STAT-3, NF-κB and AP-1. IL-10 also potentially inhibit several cytokine production such as IL-1 and TNF-α, chemokine such as MCP-1 and RANTES in activated monocyte/ macrophage, and also suppress MCP-1 in inflammatory cell population (this effect can delay monocyte/ macrophage recruitment in renal interstitium). IL-10 also inhibits dendritic cell function and T cell activation [32] . However, correlation between IL-10 expression and clinical outcome need further investigation.
We conclude that CD4 + IL-10 + expression in nephrotic syndrome patient (new-onset and rare relapses) were higher in prednisone + vitamin D3 treated group than prednisone-only treated group. This study also concluded that there is no correlation between CD4 
